Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Empagliflozin/Metformin 12.5/1000 mg vs JARDIANCE DUO under fed conditions in healthy adults
TCTR20251030003Phase 1Not yet recruiting
- Sponsor
- Bio-innova
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of empagliflozin + metformin, empagliflozin and metformin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Bio-innova. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
empagliflozin + metforminempagliflozinmetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on TCTR20251030003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20251030003.